Advancing gastrointestinal cancer diagnostics: a systematic review and meta-analysis of circulating microRNA-1246 as a non-invasive biomarker.

IF 4.6 Q2 MATERIALS SCIENCE, BIOMATERIALS ACS Applied Bio Materials Pub Date : 2024-07-01 Epub Date: 2024-05-14 DOI:10.1080/1354750X.2024.2350714

Amir Hossein Aalami, Ali Shahriari, Mohammad Mazaheri, Farnoosh Aalami, Amirhossein Sahebkar

{"title":"Advancing gastrointestinal cancer diagnostics: a systematic review and meta-analysis of circulating microRNA-1246 as a non-invasive biomarker.","authors":"Amir Hossein Aalami, Ali Shahriari, Mohammad Mazaheri, Farnoosh Aalami, Amirhossein Sahebkar","doi":"10.1080/1354750X.2024.2350714","DOIUrl":null,"url":null,"abstract":"Background: Despite numerous reports on the alterations of microRNA-1246 (miR-1246) expression level in digestive system cancers, its role in gastrointestinal cancers (GICs) remains unclear. This meta-analysis aimed to assess the diagnostic potential of circulating miR-1246 in GICs.Methods: Meta-disc version 1.4 and Comprehensive Meta-Analysis (CMA) version 3.7 software were used to calculate pooled sensitivity, specificity, likelihood ratios, diagnostic odds ratio (DOR), area under the curve (AUC), Q*index and summary receiver-operating characteristic (SROC). Subgroup analyses were conducted for cancer type, sample type and geographical region. Publication bias was assessed using Begg's and Egger's tests.Results: A total of 14 articles involving 18 studies and 1526 participants (972 cases and 554 controls) were included. The diagnostic accuracy of miRNA-1246 in GICs was as follows: pooled sensitivity: 0.81 (95% CI: 0.79 - 0.83), specificity: 0.74 (95% CI: 0.71 - 0.77), PLR: 3.315 (95% CI: 2.33 - 4.72), NLR: 0.221 (95% CI: 0.153 - 0.319), DOR: 16.87 (95% CI: 9.45 - 30.09), AUC: 0.891, and Q*-index: 0.807. No publication bias was found based on Begg's (p = 0.172) and Egger's (p = 0.113) tests.Conclusion: Circulating miR-1246 shows promise as a non-invasive biomarker for early detection of GICs.","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1354750X.2024.2350714","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/14 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Despite numerous reports on the alterations of microRNA-1246 (miR-1246) expression level in digestive system cancers, its role in gastrointestinal cancers (GICs) remains unclear. This meta-analysis aimed to assess the diagnostic potential of circulating miR-1246 in GICs.

Methods: Meta-disc version 1.4 and Comprehensive Meta-Analysis (CMA) version 3.7 software were used to calculate pooled sensitivity, specificity, likelihood ratios, diagnostic odds ratio (DOR), area under the curve (AUC), Q*index and summary receiver-operating characteristic (SROC). Subgroup analyses were conducted for cancer type, sample type and geographical region. Publication bias was assessed using Begg's and Egger's tests.

Results: A total of 14 articles involving 18 studies and 1526 participants (972 cases and 554 controls) were included. The diagnostic accuracy of miRNA-1246 in GICs was as follows: pooled sensitivity: 0.81 (95% CI: 0.79 - 0.83), specificity: 0.74 (95% CI: 0.71 - 0.77), PLR: 3.315 (95% CI: 2.33 - 4.72), NLR: 0.221 (95% CI: 0.153 - 0.319), DOR: 16.87 (95% CI: 9.45 - 30.09), AUC: 0.891, and Q*-index: 0.807. No publication bias was found based on Begg's (p = 0.172) and Egger's (p = 0.113) tests.

Conclusion: Circulating miR-1246 shows promise as a non-invasive biomarker for early detection of GICs.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

推进胃肠道癌症诊断：循环 microRNA-1246 作为非侵入性生物标记物的系统回顾和荟萃分析》。

背景：尽管有许多关于消化系统癌症中microRNA-1246（miR-1246）表达水平改变的报道，但其在胃肠道癌症（GICs）中的作用仍不清楚。这项荟萃分析旨在评估循环 miR-1246 在胃肠癌中的诊断潜力：方法：使用 Meta-disc V.1.4 和 Comprehensive Meta-Analysis V.3.7 软件计算集合灵敏度、特异性、似然比、诊断几率比、AUC、Q*指数和 SROC。根据癌症类型、样本类型和地理区域进行了分组分析。采用Begg's和Egger's检验评估发表偏倚：共纳入了 14 篇文章，涉及 18 项研究和 1,526 名参与者（972 例病例和 554 例对照）。miRNA-1246 在 GIC 中的诊断准确性如下：汇总灵敏度：0.81（95% CI：0.79 - 0.83），特异性：0.74（95% CI：0.71 - 0.77），PLR：3.315（95% CI：2.33 - 4.72），NLR：0.221（95% CI：0.153 - 0.319），DOR：16.87（95% CI：9.45 - 30.09），AUC：0.891，Q*：0.891：0.891，Q*指数：0.807：0.807.根据 Begg's 检验（P = 0.172）和 Egger's 检验（P = 0.113），未发现发表偏倚：结论：循环 miR-1246 有望成为早期检测 GIC 的非侵入性生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊